San Antonio Spurs player Victor Wembanyama is out for 2025 due to deep vein thrombosis, a similar condition to what ended ...

The Spurs are signaling optimism, with a team source telling The Athletic that Wembanyama is expected to be fully healthy and ...

The 21-year-old French phenom, who was selected No. 1 in the 2023 draft, was having an impressive sophomore season that led to him being named an NBA All-Star for the first time. He competed in the ...

The Spurs said they discovered a deep vein thrombosis upon Victor Wembanyama's return from San Francisco for the All-Star ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

The following is a summary of “Associations between a healthy lifestyle score and retinal neurovascular health,” published in ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.